Chewy Just Popped. Is the Pet Stock a Buy Now?

Chewy delivered Q4 revenue up 8.1% (adjusted) to $3.26B, matching consensus, with gross margin +90bps to 29.4% and adjusted EBITDA rising to $162.3M from $124.5M. Adjusted EPS was $0.27 (vs $0.28 prior year, which included an extra week) and GAAP profitability returned in the quarter. Management guided 2026 revenue growth of 8%-9% to $13.6B–$13.75B (above the $13.59B consensus), Q1 revenue growth of 7%-8% to $3.33B–$3.36B and adj. EPS $0.40–$0.45; SmartEquine is expected to add about $80M in 2026 sales. Stock trades at ~21x adjusted earnings; the outlook and vet-care expansion (CVC) underpin a constructive but measured investment case.

Analysis

Chewy's push into clinic-based veterinary care is a margin and customer-retention lever that investors underappreciate: in-network clinical touchpoints convert low-frequency buyers into recurring purchasers and create a proprietary clinical dataset that can be monetized via targeted pharma, diagnostics, and preventive-care subscriptions. That dataset — when combined with autoship behavioral signals — lets Chewy improve inventory turns on high-margin Rx/diets and reduce promotional spend, squeezing a few hundred basis points of gross-margin tailwind over 12–24 months if execution holds.

Second-order winners include veterinary diagnostics and pharma suppliers (e.g., IDXX, ZTS) who will see more predictable channel demand and may concede price concessions to scale via a captive distribution platform; conversely, national retailers with large store footprints are exposed to a two-front threat—Chewy's online auto-ship economics and the clinic-as-acquisition-engine that reduces the value of store traffic. Logistics providers and contract packagers could also see business mix shift toward recurring, smaller-basket shipments that favor last-mile specialists over big-box replenishment models.

Key risks are execution-intensive and time-phased: clinic rollouts require hiring credentialed clinicians, state-level regulatory compliance, and capital to convert sites, any of which could double expected rollout costs or slow expansion by 12–24 months. Competitor responses (Amazon bundling meds or Petco accelerating clinics) and macro discretionary spending shocks are plausible reversal catalysts; monitor clinical NPS, same-clinic LTV uplift, and supplier contract terms as high-frequency, leading KPIs.

Key Decisions for Investors

• Long CHWY (stock or Jan-2027 LEAPS): Buy CHWY shares for a 12–24 month horizon to capture LTV expansion and margin tailwinds from vet-care scale. Risk/reward: target +30–50% upside if clinics lift autoship and Rx mix; downside ~-30% if rollout stalls. Size as core conviction (3–6% net exposure) with a 20% trailing stop.
• Pair trade — Long CHWY / Short WOOF (Petco), 1:1 notional, 6–12 months: Isolate channel share shift toward digital + clinic model. Reward: outperformance of 200–400bps if Chewy converts high-value customers; risk: symmetric if Petco's in-store clinics drive traffic. Tight pair stop if divergence exceeds 15% adverse.
• Long IDXX (IDEXX) or call spread, 9–18 months: Buy diagnostic exposure to play secular growth in vet visits driven by clinic expansion. Reward: steady earnings multiple re-rate as consumable-linked revenue grows; risk: execution/competitive pricing leading to a 10–20% pullback—size as satellite (1–2%).
• Hedge idea — Small Short AMZN exposure vs CHWY core position for 6–12 months: Use a modest AMZN short (or buy puts) to hedge general e-commerce multiple risk and isolate pet-specific alpha. Keep hedge small (<=25% of CHWY size) — AMZN can move idiosyncratically; unwind if AMZN demonstrates targeted investments into the pet vertical.